ライフサイエンスコーパス: intestinal transplantation

1 arrier to improving long-term outcomes after intestinal transplantation.

2 to address the risk of de novo cancer after intestinal transplantation.

3 mia/reperfusion injury associated with small intestinal transplantation.

4 s commonly isolated from children undergoing intestinal transplantation.

5 -associated liver disease is reversible with intestinal transplantation.

6 ansplantation and require combined liver and intestinal transplantation.

7 ributes to ischemia-reperfusion injury after intestinal transplantation.

8 ion should prompt consideration for isolated intestinal transplantation.

9 free survival can be achieved after isolated intestinal transplantation.

10 rst-line treatment of CD20 B-cell PTLD after intestinal transplantation.

11 ion in a rodent orthotopic survival model of intestinal transplantation.

12 h PTLD from March 1999 to August 2001, after intestinal transplantation.

13 ight improve the overall outcome of isolated intestinal transplantation.

14 o-mismatch allografts for cadaveric isolated intestinal transplantation.

15 ronic intestinal rejection in a rat model of intestinal transplantation.

16 for the induction of apoptosis in rat small intestinal transplantation.

17 course and complex management that accompany intestinal transplantation.

18 and can be used for preemptive therapy after intestinal transplantation.

19 parenteral nutrition dependence and need for intestinal transplantation.

20 nting postoperative dysmotility for clinical intestinal transplantation.

21 ntestinal physiology following resection and intestinal transplantation.

22 eral nutrition in a series of children after intestinal transplantation.

23 eceiving HPN were eventually eligible for an intestinal transplantation.

24 were sent to 50 centers performing pediatric intestinal transplantation.

25 s of abdominal domain is a common problem in intestinal transplantation.

26 in generally accepted referral criteria for intestinal transplantation.

27 oxidant and anti-inflammatory effects in rat intestinal transplantation.

28 l failure patients including those requiring intestinal transplantation.

29 ning from parenteral nutrition, and need for intestinal transplantation.

30 of our prophylaxis and treatment regimens in intestinal transplantation.

31 ully selected patients and does not preclude intestinal transplantation.

32 n various solid organ transplants but not in intestinal transplantation.

33 , including 8 who were weaned from TPN after intestinal transplantation.

34 have greatly improved patient outcomes after intestinal transplantation.

35 pot specimen citrulline concentrations after intestinal transplantation.

36 inal failure is considered an indication for intestinal transplantation.

37 igate the physiology and immunology of small-intestinal transplantation.

38 rative relationships with centers performing intestinal transplantation; (3) National registries for

39 With the more frequent use of pancreatic and intestinal transplantation, a procurement procedure is n

40 dentify potential new criteria for pediatric intestinal transplantation among transplant centers in E

41 etransplantation was performed in 3 isolated intestinal transplantation and 9 multivisceral transplan

42 toring will ease sample collection following intestinal transplantation and improve the ability to de

43 is review is to update the current status of intestinal transplantation and its role in the managemen

44 help define the pool of potential donors for intestinal transplantation and propose methods for an in

45 tality in adults and children candidates for intestinal transplantation and provide recommendations o

46 sease, which may preclude them from isolated intestinal transplantation and require combined liver an

47 eaned off of HPN, 9% of the PDD subgroup had intestinal transplantation, and 10% died mostly because

48 requently, resection of localized disease or intestinal transplantation are indicated.

49 Long-term outcomes of intestinal transplantation are limited by infection and

50 tion (TPN) or more frequently considered for intestinal transplantation as part of their treatment pr

51 reventing the more widespread application of intestinal transplantation as treatment for intestinal f

52 this complication on the survival outcome of intestinal transplantation at a single center.

53 lied to stratify all patients that underwent intestinal transplantation at the University of Miami be

54 As intestinal transplantation becomes more successful, unde

55 241 patients who underwent intestinal transplantation between March 1994 and July 2

56 losure of the abdomen in patients undergoing intestinal transplantation can be extremely difficult, i

57 Referral criteria for pediatric intestinal transplantation can be improved by defining m

58 Intestinal transplantation can salvage most patients who

59 Although progress has been made in intestinal transplantation, chronic inflammation remains

60 d intestinal (IITx; n=12) and combined liver-intestinal transplantation (CLITx group; n=39).

61 As outcomes with intestinal transplantation continue to improve, its role

62 esponse to ischemia reperfusion injury after intestinal transplantation contributing to graft dysmoti

63 or ABO incompatibility may be tolerated with intestinal transplantation, despite the transplantation

64 The early outcomes of intestinal transplantation from living donors are promis

65 Intestinal transplantation has become a standard treatme

66 Intestinal transplantation has become an accepted therap

67 Intestinal transplantation has become the treatment of c

68 Intestinal transplantation has been hampered by high rat

69 Isolated intestinal transplantation has been limited by poor pati

70 Intestinal transplantation has been successfully develop

71 leocecal valve in patients receiving primary intestinal transplantation has not been performed in a s

72 Their role in intestinal transplantation has not yet been described.

73 ding changes in small bowel physiology after intestinal transplantation has received less attention.

74 Very young pediatric patients awaiting intestinal transplantation have a high mortality rate du

75 All four of those undergoing intestinal transplantation have also subsequently discon

76 The survival rates after intestinal transplantation have cumulatively improved du

77 ker for acute cellular rejection (ACR) after intestinal transplantation; however, its clinical utilit

78 marker for acute cellular rejection (ACR) in intestinal transplantation; however, its significance as

79 transplantation, and recipients of isolated intestinal transplantation (IIT)/multivisceral transplan

80 tibodies may represent a barrier to isolated intestinal transplantation (IITx).

81 on, reverses complications of TPN and avoids intestinal transplantation in the majority with few surg

82 8 months, risk factors affecting survival to intestinal transplantation include small body size and a

83 Risk of mortality at 6 months after intestinal transplantation increased when the liver is i

84 Intestinal transplantation initiates a functionally rele

85 Clinical intestinal transplantation (Int-Tx) is limited by high r

86 this function is impaired in the setting of intestinal transplantation into a NOD2 mutant recipient.

87 Intestinal transplantation is a developing therapeutic o

88 Intestinal transplantation is a feasible therapy for pat

89 Intestinal transplantation is a suitable treatment optio

90 Intestinal transplantation is known to be associated wit

91 Successful intestinal transplantation is measured by the achievemen

92 Intestinal transplantation is now an accepted therapy fo

93 Intestinal transplantation is now available for patients

94 of suitable donors and listed recipients for intestinal transplantation is small, resulting in diffic

95 The ultimate role of intestinal transplantation is still undergoing evaluatio

96 Intestinal transplantation is used in patients with shor

97 The long-term outcome of intestinal transplantations is still not favorable, whic

98 ovirus (CMV) prevention and treatment across intestinal transplantation (IT) programs is unknown.

99 diagnosis of acute and chronic rejection in intestinal transplantation (ITX) are far from being comp

100 Home parenteral nutrition (HPN) and intestinal transplantation (ITx) are the 2 treatment opt

101 n (HPN) to that among patients who underwent intestinal transplantation (ITx) at the University of Pi

102 Advances in intestinal transplantation (ITx) have resulted in improv

103 Outcomes after intestinal transplantation (ITx) have steadily improved.

104 rent rejection shortens graft survival after intestinal transplantation (ITx) in children, most of wh

105 Bacteremia occurs frequently after intestinal transplantation (ITx) in children.

106 Defining the indication and timing for intestinal transplantation (ITx) is challenging.

107 Intestinal transplantation (ITx) is severely limited by

108 any patients with intestinal failure require intestinal transplantation (ITx) to survive.

109 Since April 1994, children undergoing intestinal transplantation (ITx) underwent serial monito

110 Despite recent advances in intestinal transplantation (ITx), infection (INF) and ac

111 to intractable diarrhea often necessitating intestinal transplantation (ITx).

112 duce ischemia/reperfusion injury (IRI) after intestinal transplantation (ITX).

113 nd humoral rejection, that is, children with intestinal transplantation (ITx).

114 nts, it has not been studied in detail after intestinal transplantation (ITx).

115 rize the presence and effect of SCR in small intestinal transplantation (Itx).

116 lutionized difficult abdominal closure after intestinal transplantation (ITX).

117 d outcome of infectious enteritis (IE) after intestinal transplantation (ITx).

118 r single-center experience with living donor intestinal transplantation (LDITx) and combined living d

119 r those with life-threatening complications, intestinal transplantation may soon be an option for any

120 n lifestyle associated with long-term TPN or intestinal transplantation or both, it seems prudent to

121 d include both intestinal rehabilitation and intestinal transplantation or have active collaborative

122 One isolated intestinal transplantation patient underwent isolated en

123 re analyzed using multiple ex vivo assays in intestinal transplantation recipients.

124 ologic risk reduction in sensitized isolated intestinal transplantation recipients.

125 cal course and histopathological findings of intestinal transplantation recipients.

126 Intestinal transplantation remains a significant challen

127 The cost of parenteral nutrition compared to intestinal transplantation reveals that transplantation

128 Intestinal transplantation salvage was required in 14% a

129 If these interventions fail, intestinal transplantation should be performed expeditio

130 All patients that are referred for intestinal transplantation should undergo preliminary ma

131 disease (PTLD) has a higher incidence after intestinal transplantation than after transplantation of

132 ed parenteral nutrition is higher than after intestinal transplantation, the 1 and 2 year survival is

133 ic and functional graft protection in rodent intestinal transplantation, ultimately facilitating reci

134 Orthotopic syngenic intestinal transplantation was performed in Lewis rats a

135 Isogeneic intestinal transplantation was performed in Lewis rats w

136 Orthotopic intestinal transplantation was performed in rats.

137 es in a group of 22 pediatric patients after intestinal transplantation, we assessed mucosal disaccha

138 specific risk factors impacting survival to intestinal transplantation, we performed a 4-year instit

139 In a pig model of intestinal transplantation, we previously showed that he

140 ast year, initial attempts at adult to child intestinal transplantation were carried out with some su

141 undergoing concomitant or prior liver and/or intestinal transplantation were excluded from analysis.

142 undergoing concomitant or prior liver and/or intestinal transplantation were not included in the anal

143 atients awaiting kidney, liver, pancreas, or intestinal transplantation were pretreated with about 5

144 Early attempts with intestinal transplantation were unsuccessful as a conseq

145 milarly, allogeneic and syngeneic orthotopic intestinal transplantations were performed in tacrolimus

146 Allogeneic and syngeneic orthotopic intestinal transplantations were performed in untreated

147 A successful liver/small intestinal transplantation with a blood group O donor to

148 ed patients to successfully undergo isolated intestinal transplantation with acceptable short-term ou

149 sion-free closure of the fascial layer after intestinal transplantation with complications similar to